WATCHMAN integrated laac solution

WATCHMAN™
Integrated LAAC Solutions

A PROVEN PATHWAY FROM ACCESS TO HEALING

A complete integrated solution for Left Atrial Appendage Closure. From transseptal access to sealing and healing, with precision, control, and confidence at every step.

600,000+

patients treated with the WATCHMAN™ Implant worldwide 1All WATCHMAN models

20+

years of clinical experience behind the WATCHMAN™portfolio

98,6+

effective closure (≤3 mm) at 4 months (CHAMPION-AF)

99%

implant success rate in the CHAMPION-AF, PINNACLE FLX, OPTION, HEAL LAA Trials

* Successful delivery and release of WATCHMAN FLX – WATCHMAN FLX Pro devices

The WATCHMAN™ Integrated LAAC Solution

WATCHMAN FLX™ Pro, TruSteer™ and VersaCross Connect™, engineered to work together, delivering a seamless end-to-end procedural workflow for Left Atrial Appendage Closure. From transseptal access to healing.

  • The WATCHMAN Integrated Solution provides great control at every stage, thanks to a streamlined procedure and predictable, effective performance.
  • The simplified, streamlined procedure enhances workflow efficiency while maintaining consistency and safety.
WATCHMAN FLX Pro

WATCHMAN FLX™ Pro

Built on the trusted foundation of WATCHMAN FLX, WATCHMAN FLX™ Pro represents the next evolution in LAAC.

Featuring HEMOCOAT™ Technology, enhanced visibility through radiopaque markers, and a new 40 mm size, WATCHMAN FLX™ Pro is designed to support confidence across a broader range of anatomies.

Product Page

WATCHMAN TruSteer

WATCHMAN TruSteer™

Designed for precision for every anatomy, WATCHMAN TruSteer™ provides bidirectional steering for optimal coaxial alignment and controlled device positioning even in challenging anatomies.

Product Page

VersaCross Connect

LAAC Access Solution

VersaCross Connect™

Designed for precise left atrial access, VersaCross Connect combines RF puncture, guidewire support and access retention in a single exchangeless solution to support a more streamlined WATCHMAN workflow.

Product Page

Clinical Evidence

CHAMPION-AF trial

CLINICAL EVIDENCE

CHAMPION-AF

The CHAMPION-AF clinical trial, comparing WATCHMAN FLX™ to NOAC in NVAF patients, met primary and secondary endpoints at 36 months. 

View Clinical Data

OPTION trial

CLINICAL EVIDENCE

OPTION

The OPTION clinical trial, comparing WATCHMAN FLX™ to OAC after cardiac ablation, met primary and secondary endpoints at 36 months. 

View Clinical Data

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.